Patient info

Emollient Bath Oil – Summary of Product Characteristics (SmPC) for healthcare professionals

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet: how to take, side effects, pregnancy and breast-feeding.

Updated:

Summary of Product Characteristics (SmPC) - Emollient Bath oil

1 NAME OF THE MEDICINAL PRODUCT

Emollient Bath Oil

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Light Liquid Paraffin 63.4% w/w

3 PHARMACEUTICAL FORM

Bath oil

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Emollient Bath Oil is indicated in the treatment of contact dermatitis, atopic dermatitis, senile pruritus ichthyosis and related dry skin conditions. Emollient Bath Oil deposits a thin film of oil over the skin. This retards moisture loss and hydrates the skin. Emollient Bath Oil is particularly suitable for infant bathing. The preparation also overcomes the problem of cleansing the skin in conditions where the use of soaps, soap substitutes and colloid or oat-meal baths proves irritating.

4.2 Posology and method of administration

Emollient Bath Oil should always be used with water, either added to water or applied to wet skin.

Adult Bath: Add ½ - 1½ capfuls to an 8 inch bath of water. Soak for 10-20 minutes. Pat dry.

Infant Bath: Add ¼ - 1 capful to a basin of water. Apply gently over entire body with a sponge. Pat dry.

Skin cleansing: Rub a small amount of oil into wet skin. Rinse and pat dry.

Where conditions permit, and particularly in cases of extensive areas of dry skin, Emollient Bath Oil should be used as a bath oil, ensuring complete coverage by immersion. In addition to the therapeutic benefits, this method of use provides a means of sedating tense patients, particularly relevant in cases of acute pruritic dermatoses where relaxation of tension appears to relieve symptoms. The product is suitable for use in adults, children and the elderly.

4.3 Contraindications

Do not use on individuals with hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

If a rash or skin irritation occurs, stop using this product and consult your doctor.

Care should be taken against slipping especially when entering or leaving the bath or shower.

Healthcare professionals should instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.

For external use only.

Keep all medicines out of the sight and reach of children.

4.5 Interaction with other medicinal products and other forms of interaction

No significant interactions are known.

4.6 Fertility, pregnancy and lactation

Fertility

There are no data on the use of Light Liquid Paraffin on human fertility.

Pregnancy

No effects during pregnancy are anticipated, since systemic exposure to Light Liquid Paraffin is expected to be low.

Lactation

It is not known if Light Liquid Paraffin is excreted in human milk. Risk to the infant is likely to be low since systemic exposure is low. Patients should be advised to ensure that any residual product is fully washed off the breast prior to breast feeding.

4.7 Effects on ability to drive and use machines

None would be anticipated.

4.8 Undesirable effects

Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1,000 and < 1/100), rare (≥1/10, 000 and <1/1,000); very rare (<1/10, 000) and not known (cannot be estimated from the available data).No significant effects have been reported with topical use.

Post-marketing data

System Organ ClassFrequency - rare
Immune system disordersApplication site hypersensitivity reactions including application site dermatitis
Skin and subcutaneous tissue disordersApplication site reactions including application site irritation, rash, erythema, pruritus

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose

Signs and symptoms

The product is intended for cutaneous use only. Accidental ingestion may cause gastrointestinal irritation with nausea, vomiting and diarrhoea.

Treatment

In case of accidental ingestion, management should be as clinically indicated or as recommended by the national poisons centre, where available.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Light Liquid Paraffin is a lubricant and emollient. It forms an occlusive film on the skin retarding water loss from the stratum corneum and aiding in the prevention of dryness.

5.2 Pharmacokinetic properties

Little information is available on the pharmacokinetics of light liquid paraffin. Intestinal absorption of small amounts may occur. It is not metabolised.

5.3 Preclinical safety data

No relevant data are available.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Isopropyl Myristate B.P. Polyethoxylated (3) Lauryl Alcohol HSE. Perfume C2106 HSE.

6.2 Incompatibilities

No significant incompatibilities are known.

6.3 Shelf life

Two years.

6.4 Special precautions for storage

Store below 25°C.

6.5 Nature and contents of container

A rectangular white HDPE bottle fitted with a ridged white HDPE screw-cap closure with an expanded polyethylene (EPE) liner.

Pack sizes: 250ml & 500ml.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No further information.

7 MARKETING AUTHORISATION HOLDER

Tillomed Laboratories Limited

220 Butterfield

Great Marlings

Luton

LU2 8DL

United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 11311/0778

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

10 DATE OF REVISION OF THE TEXT

04/09/2025

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 11311/0778

Last revision stated in the text: 4 September 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Emollient Bath oil

Excipients Isopropyl Myristate B.P. Polyethoxylated (3) Lauryl Alcohol HSE. Perfume C2106 HSE.
Shelf life Two years.
Storage Store below 25°C.
Marketing authorisation PL 11311/0778
Marketing authorisation holder Tillomed Laboratories Limited

Sources: the MHRA product information (products.mhra.gov.uk). Contains public sector information licensed under the Open Government Licence v3.0.